<DOC>
	<DOCNO>NCT00511238</DOCNO>
	<brief_summary>To evaluate overall response rate safety tolerability carfilzomib subject relapse refractory multiple myeloma . Patients must receive prior treatment bortezomib either thalidomide lenalidomide refractory last treatment .</brief_summary>
	<brief_title>Phase 2 Study Carfilzomib Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Disease Related Multiple myeloma Subjects must measurable disease define one following : Serum Mprotein ≥ 1 g/dL Urine Mprotein ≥ 200 mg/24 hour Serum FLC ≥ 10 mg/dL abnormal ratio ( A0 Only ) Quantitative immunoglobulin level use nephelometry turbidometry ( protein electrophoresis felt unreliable Mprotein measurement ) ( A0 Only ) Subjects must responsive ( i.e. , achieve MR well ) firstline , standard care therapy Refractory recently receive therapy . Refractory disease define ≤ 25 % response progression therapy within 60 day completion therapy . Subjects must receive ≥ 2 prior regimen relapse disease . Induction therapy stem cell transplant consider one regimen ( A1 Only ) Subjects must receive prior treatment bortezomib , either thalidomide lenalidomide Subjects must receive alkylating agent either alone combination myeloma treatment ( history stem cell transplant acceptable ) ( A1 Only ) Subjects must receive anthracycline either alone combination myeloma treatment , unless clinically indicate ( A1 Only ) Demographic Males females &gt; 18 year age Life expectancy three month Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Laboratory Adequate hepatic function , bilirubin le 2.0 time upper limit normal , AST ALT less 3.0 time upper limit normal Uric acid within normal range ( A0 Only ) Total white blood cell ( WBC ) count ≥ 2.0 × 109/L , absolute neutrophil count ( ANC ) ≥ 1.0 × 109/L , hemoglobin ≥ 8.0 g/dL , platelet count ≥ 50.0 × 109/L ( A0 Only ) Absolute neutrophil count &gt; 1,000/mm3 , hemoglobin &gt; 8.0 g/dL , platelet count &gt; 50,000/mm3 ( A1 Only ) Subjects platelet transfusion independent Screening ANC independent GCSF GMCSF support ≥ 1 week pegylated GCSF ≥ 2 week Subjects may receive red blood cell ( RBC ) platelet transfusion receive supportive care erythropoietin darbepoetin accordance institutional guideline Calculated measured creatinine clearance ≥ 30 mL/minute , calculate use formula Cockcroft Gault [ ( 140 Age ) X Mass ( kg ) / ( 72 X Creatinine mg/dL ) ] . Multiply result 0.85 female . Ethical / Other Written inform consent accordance federal , local , institutional guideline Female subject childbearing potential must negative serum pregnancy test within seven day first dose agree use dual method contraception 3 month follow last dose drug . Post menopausal female ( &gt; 45 year old without menses &gt; 1 year ) surgically sterilize female exempt pregnancy test . Male subject must use effective barrier method contraception study 3 month follow last dose sexually active female childbearing potential . Disease Related Multiple Myeloma IgM ( A1 Only ) Subjects fail achieve least confirmed MR ( ≥ 25 % reduction Mprotein ≥ 6 week ) ( A1 Only ) Subjects nonsecretory multiple myeloma , define &lt; 1 g/dL Mprotein serum &lt; 200 mg/24 hr Mprotein urine Subjects disease measurable serum free light chain ( SFLC ) analysis ( A1 Only ) Glucocorticoid therapy ( prednisone &gt; 10 mg/day orally equivalent ) within last three week POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) Plasma cell leukemia Chemotherapy approve investigative anticancer therapeutic include steroid therapy within three week prior first dose Radiation therapy immunotherapy previous four week ; localize radiation therapy within 1 week prior first dose Participation investigational therapeutic study within three week within five drug halflives ( t1/2 ) prior Day 1 , whichever time great Prior treatment carfilzomib Concurrent Conditions Major surgery within three week Day 1 Congestive heart failure ( New York Heart Association class III IV ) , symptomatic cardiac ischemia , cardiomyopathy , conduction abnormality uncontrolled conventional intervention , myocardial infarction previous six month , LVEF &lt; 40 Acute active infection require systemic antibiotic , antiviral antifungal within 2 week prior first dose Known suspected HIV infection subject HIV seropositive Active hepatitis A , B , C infection Nonhematologic malignancy within past three year except ) adequately treat basal cell squamous cell skin cancer , b ) carcinoma situ cervix , c ) prostate cancer &lt; Gleason Grade 6 stable PSA Subjects treatment relate myelodysplastic syndrome Significant neuropathy ( Grade 3 , 4 Grade 2 pain ) time study initiation Subjects require program oral intravenous fluid hydration contraindicate , e.g. , due preexist pulmonary , cardiac renal impairment ( A1 Only ) Subjects know suspected amyloidosis ( A1 Only ) Subjects pleural effusion require thoracentesis ascites require paracentesis ( A1 Only ) Any clinically significant medical disease condition , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent ( A1 Only ) Ethical / Other Female subject pregnant lactate Serious psychiatric medical condition could interfere treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Onyx</keyword>
	<keyword>PR171</keyword>
	<keyword>carfilzomib</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
</DOC>